Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia Academic Article uri icon

Overview

MeSH Major

  • Hematologic Neoplasms
  • Picornaviridae Infections
  • Respiratory Tract Infections
  • Rhinovirus

abstract

  • Guadecitabine has promising clinical activity and an acceptable safety profile and thus warrants further development in this population. Cancer 2018;124:325-34. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

publication date

  • January 15, 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.31138

PubMed ID

  • 29211308

Additional Document Info

start page

  • 325

end page

  • 334

volume

  • 124

number

  • 2